Literature DB >> 11005618

Interleukin-8 and procalcitonin in early diagnosis of early severe bacterial infection in critically ill neonates.

B Bonac1, M Derganc, B Wraber, S Hojker.   

Abstract

We studied the value of serum interleukin-8 (IL-8) and procalcitonin (PCT) in the early diagnosis of early severe bacterial infection in 58 critically ill ventilated neonates. ELISA was used for determining IL-8 and immunoluminometric assay for PCT. IL-8 and PCT were compared with routinely used serum C-reactive protein (CRP). Neonates were divided into four groups: Ia--proven severe bacterial infection (n = 9), Ib--clinical sepsis (n = 16), II--respiratory distress without bacterial infection (n = 12), and III--various types of neonatal distress (n = 21). Sera were collected on admission, at 24 h and 48 h after admission. There was no significant difference between groups Ia and Ib for either parameter at any time interval. Significant difference was found between group Ia+b (septic neonates) and group II for PCT and CRP at 24 and 48 h, but not for IL-8. There was no difference between group Ia+b and group III except for CRP at 24 h. Diagnostic accuracy was best for PCT on admission and for CRP at 24 h. Serum PCT and IL-8 are not specific markers for early severe bacterial infection in critically ill neonates and are not better than CRP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005618

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  8 in total

1.  Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein.

Authors:  Maja Pavcnik-Arnol; Sergej Hojker; Metka Derganc
Journal:  Intensive Care Med       Date:  2004-05-04       Impact factor: 17.440

2.  Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children.

Authors:  Maja Pavcnik-Arnol; Sergej Hojker; Metka Derganc
Journal:  Intensive Care Med       Date:  2007-04-05       Impact factor: 17.440

3.  Sensitive noninvasive marker for the diagnosis of probable bacterial or viral infection.

Authors:  Saeed A Jortani; Michael J Pugia; Ronald J Elin; Meera Thomas; Edward P Womack; Todd Cast; Roland Valdes
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

4.  Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study.

Authors:  Martin Stocker; Wim C J Hop; Annemarie M C van Rossum
Journal:  BMC Pediatr       Date:  2010-12-08       Impact factor: 2.125

5.  The diagnostic utility of procalcitonin, interleukin-6 and interleukin-8, and hyaluronic acid in the Norwegian consensus definition for early-onset neonatal sepsis (EONS).

Authors:  Britt Nakstad
Journal:  Infect Drug Resist       Date:  2018-03-08       Impact factor: 4.003

6.  Biomarkers for diagnosis of neonatal infections: A systematic analysis of their potential as a point-of-care diagnostics.

Authors:  Mahbuba Meem; Joyanta K Modak; Roman Mortuza; Mahboob Morshed; Mohammad Shahidul Islam; Samir K Saha
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

7.  Early-Onset Neonatal Sepsis: Still Room for Improvement in Procalcitonin Diagnostic Accuracy Studies.

Authors:  Claudio Chiesa; Lucia Pacifico; John F Osborn; Enea Bonci; Nora Hofer; Bernhard Resch
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

Review 8.  Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis.

Authors:  Giuseppe Pontrelli; Franco De Crescenzo; Roberto Buzzetti; Alessandro Jenkner; Sara Balduzzi; Francesca Calò Carducci; Donato Amodio; Maia De Luca; Sara Chiurchiù; Elin Haf Davies; Giorgia Copponi; Alessandra Simonetti; Elena Ferretti; Valeria Di Franco; Virginia Rasi; Martina Della Corte; Luca Gramatica; Marco Ciabattini; Susanna Livadiotti; Paolo Rossi
Journal:  BMC Infect Dis       Date:  2017-04-24       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.